Germinal matrix hemorrhage is induced by stereotaxic injection of collagenase into the germinal matrix of P7 Sprague-Dawley rats. Hemoglobin assay, western blot, immunofluorescence and neurobehavioral tests were used to test the effects of BLVRA on hematoma resolution and anti-inflammatory response. We showed that BLVRA triggered a signaling cascade that ameliorated post-hemorrhagic neurological deficits in both short-term and long-term neurobehavioral tests in a GMH rat model. Specifically, BLVRA inhibited toll-like receptor 4 (TLR4) expression by translocating to the nucleus in an endothelial nitric oxide (eNOS)/nitric oxide (NO)-dependent manner. BLVRA also induced the upregulation of CD36 scavenger receptor level in microglia/microphages, of which the prominent role is to enhance hematoma resolution. However, the beneficial effects of BLVRA were abolished with the knockdown of eNOS, indicating that the eNOS/NO system is an important downstream factor of BLVRA. Our results demonstrate a mechanism of BLVRA modulating hematoma resolution and suppressing inflammation through eNOS/NO/TLR4 pathway in the GMH rat model.
Introduction
Germinal matrix hemorrhage (GMH) results from the rupture of immature blood vessels in the subventricular region of premature infants (Ballabh, 2010) . It occurs in up to 20% of infants delivered at < 32 weeks gestation. Its common complications include significant developmental delay, mental retardation, hydrocephalus and cerebral palsy (Heron et al., 2010) . Current clinical management is limited to improving symptoms in GMH neonates but does not confer further protective or prophylactic effects. Thus, it is critically important to identify new approaches to modulate disease progression in GMH patients.
Hematoma toxicity is caused by the cytotoxic substances released from both activated neuroglia and hematogeous cells (Aronowski and Hall, 2005; Xi et al., 2006; Egawa et al., 2017) . In GMH, the blood clot can also obstruct cerebrospinal fluid circulation, contributing to posthemorrhagic hydrocephalus development (Aquilina et al., 2011; Cherian et al., 2004; Dang et al., 2017) . Clinical studies use hematoma volume as a prognostic indicator, which negatively correlates with functional recovery (Keep et al., 2005) .
Biliverdin reductase (BVR) is a well-characterized enzyme in the heme degradation pathway that converts biliverdin to bilirubin. Two isoforms of BVR were named biliverdin reductase A (BLVRA) and biliverdin reductase B (BLVRB). Both of them can generate bilirubin but only BLVRA, also called Biliverdin-IX-alpha reductase, is a metabolic enzyme that converts biliverdin-IX-alpha into an antioxidant and antinitrosative molecule bilirubin-IX-alpha in this degradation pathway (Kapitulnik and Maines, 2009; Maines, 2005; Franklin et al., 2009 ). In addition, BLVRA decreased Toll-like receptor-4 (TLR4) expression and regulated inflammatory cytokines secretion in monocytes (Wegiel et al., 2011) . Although the anti-inflammatory role of BLVRA is more wellestablished, the role of bilirubin in the brain remains controversial (Huang et al., 2002; Loftspring et al., 2011; Fereshtehnejad et al., 2012) . It is possible that bilirubin, in the presence of BLVRA, can confer more protective effects rather than toxic effects. However, more studies are warranted to understand the underlying mechanisms of bilirubin in brain diseases.
Nitric Oxide (NO) is an important intercellular messenger in the central/peripheral nervous system. Endothelial nitric oxide synthase (eNOS), neuronal nitric oxide synthase (nNOS), and inducible nitric https://doi.org/10.1016/j.nbd.2017.11.017 Received 6 September 2017; Received in revised form 11 November 2017; Accepted 30 November 2017
